Neuropace Inc. (NPCE) 2024 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2024. Neuropace Inc. is a medical device company focused on treating drug-resistant focal epilepsy with its RNS System, the only commercially available brain-responsive neuromodulation system. The device delivers personalized, real-time treatment at the seizure source and records continuous brain activity data. As of December 31, 2024, over 6,000 patients had received the RNS System. The company is an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $79.9 million | $65.4 million |
| Gross Profit | $59.1 million | $48.1 million |
| Gross Margin | 73.9% | 73.6% |
| Net Loss | $(27.1) million | $(33.0) million |
| Operating Loss | $(21.7) million | $(27.2) million |
| Cash Used in Operating Activities | $(17.9) million | $(19.7) million |
| Cash, Cash Equivalents & Short-Term Investments | $52.8 million | $66.5 million |
| Outstanding Debt (Term Loan) | $59.5 million (net of discount) | $57.0 million (net of discount) |
| Accumulated Deficit | $(531.0) million | $(503.8) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 22% to $79.9 million, driven by higher RNS System unit sales and increased sales of DIXI Medical products (which represented 17% of total revenue in 2024 vs. 15% in 2023).
- Profitability Improvement: Net loss narrowed by 18% to $27.1 million, and operating loss decreased by 20% to $21.7 million, primarily due to revenue growth outpacing expense increases.
- Expense Trends: Research and Development (R&D) expenses rose 14% to $23.7 million due to increased personnel and product development costs. Selling, General, and Administrative (SG&A) expenses increased 5% to $57.1 million, driven by sales force expansion.
- Debt Structure: The company amended its Term Loan in May 2024 to extend the maturity date to September 30, 2026, and eliminated the Pay-In-Kind (PIK) interest option after June 30, 2024.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to continue incurring net losses for the foreseeable future. Growth strategies include expanding access to the RNS System outside of Level 4 Comprehensive Epilepsy Centers (CECs) into the community setting, broadening indications to include patients with generalized epilepsy and those under age 18, and leveraging data assets for AI-driven therapy optimization. The company plans to file expanded label submissions with the FDA in the second half of 2025.
Recent Capital Activity: In February 2025, the company completed a follow-on offering raising approximately $69.8 million in net proceeds. $49.5 million was used to repurchase shares from a significant stockholder (KCK Ltd.), with the remainder designated for general corporate purposes, R&D, and debt reduction.
Key Risks:
- Regulatory Approval: Growth depends on FDA approval for expanded indications (generalized epilepsy and pediatric patients). Delays in FDA reviews could harm growth potential.
- Debt Covenants: The Term Loan requires minimum annual revenue thresholds ($70.0 million for 2024 and 2025) and minimum cash balances. Failure to comply could trigger an event of default.
- Supply Chain: The company relies on single-source suppliers for critical components (e.g., batteries, printed circuit assemblies), creating vulnerability to supply shortages.
- Reimbursement: Continued commercial success depends on maintaining adequate reimbursement from third-party payors for implant procedures and ongoing care.
Investor Verification Checklist
- Debt Covenant Compliance: Verify that the company met the $70.0 million minimum annual revenue covenant for 2024 and maintains the required minimum cash balance to avoid default on the Term Loan.
- Regulatory Timeline: Monitor the status of the NAUTILUS (generalized epilepsy) and RESPONSE (pediatric) clinical trials and the expected FDA submission dates in late 2025.
- Capital Runway: Assess the impact of the February 2025 capital raise on the company's liquidity and ability to fund operations for the next 12+ months.
- Supply Chain Resilience: Review any updates regarding single-source suppliers for critical components and the company's inventory levels.
- Revenue Mix: Track the percentage of revenue derived from DIXI Medical products versus the RNS System to understand margin stability and dependency on the distribution agreement (renewal notice due April 3, 2025).